CN103156819A - Benzoic acid alogliptin composition troche and preparation method thereof - Google Patents
Benzoic acid alogliptin composition troche and preparation method thereof Download PDFInfo
- Publication number
- CN103156819A CN103156819A CN2013101058594A CN201310105859A CN103156819A CN 103156819 A CN103156819 A CN 103156819A CN 2013101058594 A CN2013101058594 A CN 2013101058594A CN 201310105859 A CN201310105859 A CN 201310105859A CN 103156819 A CN103156819 A CN 103156819A
- Authority
- CN
- China
- Prior art keywords
- syr
- parts
- composition
- tablet
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 title claims abstract description 103
- 239000000203 mixture Substances 0.000 title claims abstract description 94
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 title abstract description 13
- 239000005711 Benzoic acid Substances 0.000 title abstract description 6
- 235000010233 benzoic acid Nutrition 0.000 title abstract description 6
- 229960001667 alogliptin Drugs 0.000 title abstract 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 38
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 30
- 229930195725 Mannitol Natural products 0.000 claims abstract description 30
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000000594 mannitol Substances 0.000 claims abstract description 30
- 235000010355 mannitol Nutrition 0.000 claims abstract description 30
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 29
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 29
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 29
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 27
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 19
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 19
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 19
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 17
- 230000008569 process Effects 0.000 claims abstract description 16
- 239000011248 coating agent Substances 0.000 claims description 34
- 238000000576 coating method Methods 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 33
- 238000004132 cross linking Methods 0.000 claims description 25
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 25
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 25
- 239000008187 granular material Substances 0.000 claims description 23
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 21
- 239000007864 aqueous solution Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 9
- 239000004615 ingredient Substances 0.000 claims description 8
- 238000007873 sieving Methods 0.000 claims description 7
- 239000007916 tablet composition Substances 0.000 claims description 6
- 239000007779 soft material Substances 0.000 claims description 5
- 238000007664 blowing Methods 0.000 claims description 4
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000007888 film coating Substances 0.000 claims description 4
- 238000009501 film coating Methods 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 19
- 238000004090 dissolution Methods 0.000 abstract description 7
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 1
- 229960001681 croscarmellose sodium Drugs 0.000 abstract 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 abstract 1
- 229940057948 magnesium stearate Drugs 0.000 abstract 1
- 229960001855 mannitol Drugs 0.000 abstract 1
- 229920002994 synthetic fiber Polymers 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 239000002994 raw material Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000004811 liquid chromatography Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000013341 scale-up Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 229950005770 hyprolose Drugs 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 208000017184 Glucagon secretion disease Diseases 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960001056 dimemorfan Drugs 0.000 description 1
- KBEZZLAAKIIPFK-NJAFHUGGSA-N dimemorfan Chemical compound C1C2=CC=C(C)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 KBEZZLAAKIIPFK-NJAFHUGGSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to the field of pharmacy, and discloses a benzoic acid alogliptin composition troche and a preparation method thereof. The effective components of the benzoic acid alogliptin composition troche comprise benzoic acid alogliptin, mannitol, microcrystalline cellulose, croscarmellose sodium, magnesium stearate and 5% hydroxy propyl cellulose aqueous liquor. The synthetic materials are easy to obtain and low in cost. The troche is quick in disintegration speed, high in dissolution rate, good in stability, accurate in dosage and convenient to take and carry. The benzoic acid alogliptin composition troche is simple in step, short in production period, low in production cost and suitable for industrialized application, and the technical process is easy to control,.
Description
Technical field
The present invention relates to medical domain, disclose a kind of SYR-322 composition tablet and preparation method thereof.
Background technology
Type 2 diabetes mellitus is a kind of due to multiple dysbolismus, comprises that insulin secretion is complete, liver is replied and insulin peripheral tissue is impaired, the gradual disappearance of β cell, glucagon secretion disorder and incretin hinder a kind of glycemic control that causes disorderly.This sick sickness rate worldwide increases year by year, expectation will from 2000 2.8% be increased to 4.4% of the year two thousand thirty.Ill total number of persons from 2000 17,100 ten thousand rise to 36,600 ten thousand of the year two thousand thirty.
In type 2 diabetes mellitus, a part of patient is take insulin resistant as main, and how fat patient is, and because of insulin resistant, insulin sensitivity descends, and in blood, insulin increases to compensate its insulin resistant, but relative patient's hyperglycemia, insulin secretion is relative deficiency still.This type of patient's early symptom is not obvious, but just macrovascular and the microvascular complication of clarifying a diagnosis before of being everlasting.How Diet Therapy and the oral polysaccharide medicine that falls can be effective.Another part patient needs the supplemented with exogenous insulin clinically take defect of insulin secretion as main.
Egelieting is the DPP-4 activity inhibitor of highly selecting, and can promote by the plasma concentration that improves GLP-1 in body the secretion with sugared concentration dependent insulin.Therefore, promote that when hypoglycemia insulin secretion can not increase the weight of the hypoglycemia symptom.
SYR-322 sheet, chinesization formal name used at school are 2-(6-((3R)-3-amino piperidine-1-yl)-3-methyl-2,4-dioxy-3, the base of 4-dihydro-pyrimidin-1(2H)) methyl) benzonitrile list benzoate, chemical formula C
18H
21N
5O
2C
7H
6O
2, molecular weight 461.5, chemical structural formula is as follows:
Produced by Japanese Takeda company the earliest, disintegration rate is slow, dissolution rate is low and the shortcoming of inconvenient use but have.
Summary of the invention
The first purpose of the present invention is to provide a kind of SYR-322 composition tablet, the effective ingredient of described SYR-322 composition tablet is SYR-322, mannitol, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, magnesium stearate and 5% hydroxypropyl cellulose aqueous solution, have that synthesis material is easy to get, cost is low, and disintegration rate is fast, dissolution rate is high, good stability, dosage accurately, taking convenience, the characteristics such as be easy to carry.
In order to reach above technique effect, technical scheme of the present invention is as follows:
Produce the SYR-322 composition tablet of 25mg specification, in parts by weight, the effective ingredient of described SYR-322 composition tablet is 15 parts of 34 parts of SYR-322s, 45 parts, mannitol, 68 parts of microcrystalline Cellulose, 1.5 parts of cross-linking sodium carboxymethyl celluloses, 0.8 part of magnesium stearate and 5% hydroxypropyl cellulose aqueous solutions.
Produce the SYR-322 composition tablet of 12.5mg specification, in parts by weight, the effective ingredient of described SYR-322 composition tablet is 15 parts of 17 parts of SYR-322s, 62 parts, mannitol, 68 parts of microcrystalline Cellulose, 1.5 parts of cross-linking sodium carboxymethyl celluloses, 0.8 part of magnesium stearate and 5% hydroxypropyl cellulose aqueous solutions.
SYR-322 composition tablet of the present invention is take SYR-322 as active constituents of medicine, and the hydroxypropyl cellulose aqueous solution that is equipped with certain mannitol, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, magnesium stearate and 5% is made.
Because SYR-322 itself is poorly soluble, for increasing disintegration time and the dissolution of tablet, add cross-linking sodium carboxymethyl cellulose as disintegrating agent, add hydroxypropyl cellulose aqueous solution as binding agent, add mannitol and microcrystalline Cellulose as filler, add magnesium stearate as lubricant.
Cross-linking sodium carboxymethyl cellulose is the ether of water-soluble cellulose, and it is sodium-salt type that 70% carboxyl is approximately arranged, have larger draw moist, existence due to cross-bond, water insoluble, the water that can absorb the several times amount in water expands and insoluble, has disintegration preferably and compressibility.
Hydroxypropyl cellulose is water-soluble and multiple organic solvent at normal temperatures, as: absolute methanol, ethanol, isopropyl alcohol, propylene glycol, dichloromethane, also dissolve in acetone, chloroform, toluene and cellosolve, solution is all transparent, be good thermoplastic, have good film property, institute's film forming is very tough and tensile, glossiness is good, and elasticity is abundant; Ash is extremely low, makes this product have good caking property, and is very stable as emulsion tackify use, and good dispersion.
Mannitol (Mannitol) claim again D-mannital, is the hexahydroxylic alcohols that a kind of people are familiar with, with sorbitol be isomers.It is a kind of non-hygroscopic, odorless, white or colourless crystalline powder.Mannitol has pleasant sweet taste, and its sugariness is 0.55-0.65 times of sucrose, has the general character of multi-sugar alcohol.Mannitol is a kind of functional Sugar Alcohol that enters the earliest people's life.In functional Sugar Alcohol, mannitol is unique a kind of hexabasic alcohol that is difficult for the moisture absorption, has simultaneously the characteristics such as sugariness is suitable, heat is low, have no side effect.In the human physiological metabolism, it is the same with other functional sugar alcohol, has with insulin to have nothing to do, and does not improve the characteristics such as blood glucose value, unlikely dental caries, can be used as the sweeting agent of diabetes patient, adiposis patient.
Microcrystalline Cellulose is a kind of tasteless, imperceptible white corynebacterium cellular granule, and it does not have fibroid and mobility is extremely strong, has higher reactivity worth in carboxymethyl acidylate, acetylation, esterification process, and is very favourable to chemical modification.Owing to having hydrogen bond between the microcrystalline Cellulose molecule, hydrogen bond association during pressurized, admittedly have the compressibility of height, simultaneously, after the tablet of compacting ran into liquid, it is inner that moisture enters rapidly the tablet that contains microcrystalline Cellulose, hydrogen bond ruptures at once.Microcrystalline Cellulose in Dimemorfan phosphate tablet composition of the present invention has improved hardness, disintegrative and the compressibility of tablet greatly.
Magnesium stearate is hydrophobic lubricant, and its quality is very soft, and is therefore main as lubricant; play and fill and lead up the recessed effect in particle surface hole, the packing interaction after using between granule dies down, and is easy to each other slide; easily and the granule mixing, after tabletting, unilateral smooth and beautiful appearance, most widely used.
The invention also discloses a kind of preparation method of SYR-322 composition tablet, comprise the following steps:
(1) sieve: SYR-322 is crossed the 90-110 mesh sieve, with mannitol, microcrystalline Cellulose and the cross-linking sodium carboxymethyl cellulose 70-95 mesh sieve that sieves respectively;
(2) mix: it is standby that the SYR-322 that weighs up according to quantity after sieving, mannitol, microcrystalline Cellulose and cross-linking sodium carboxymethyl cellulose mix homogeneously get the first mixture;
(3) granulate: 5% the hydroxypropyl cellulose aqueous solution that will weigh up adds soft material processed in the first mixture, granulates after crossing the 20-25 mesh sieve;
(4) granule of step (3) is dried to moisture at 60 ℃ and is not more than 3.5%, cross granulate after the 15-25 mesh sieve, then add the magnesium stearate mix homogeneously that weighs up, measure intermediate content after tabletting namely get the SYR-322 tablet composition.
Preferably, the SYR-322 described in step (1) is crossed 100 mesh sieves, and described mannitol, microcrystalline Cellulose and cross-linking sodium carboxymethyl cellulose are crossed respectively 80 mesh sieves.
Preferably, sieving as crossing 24 mesh sieves in step (3).
Preferably, sieving as crossing 20 mesh sieves in step (4).
Preferably, the tabletting process tablet hardness in step (4) is controlled and is not less than 8Kg/mm2.
Adopt the effect that above-mentioned preparation method has to be: step is simple, and technical process is easily controlled, and is with short production cycle, and production cost is low, is fit to industrial applications.
In order to reach better technique effect, the invention also discloses a kind of SYR-322 composition film garment piece, in parts by weight, adopt above-described SYR-322 composition tablet and stomach dissolved film coating pre-mix dose to make;
150 parts of described SYR-322 composition tablets;
Described stomach dissolved film coating pre-mix dose is made by the Opadry coating powder of 16.0-16.5 part and the water of 84 parts.
In order to reach better technique effect, the present invention also provides the preparation method of above-mentioned SYR-322 composition film garment piece, comprises the following steps:
(1) weigh up Opadry coating powder and water, be mixed and made into coating solution, standby, preferably adopt purified water;
(2) weighing up the SYR-322 composition tablet puts in coating pan, adjusting the coating pan rotating speed is 5-10 rev/min, controlling inlet temperature is that 55-65 ℃ of blowing hot-air makes plain sheet temperature reach 35-45 ℃, spray into the described coating solution of step (1) until coating weightening finish 2.0%～4.0%, the stop-spraying coating solution, determine whether be rotated further coating pan depending on unilateral adhesion degree, then advance drying, namely get SYR-322 composition film garment piece.
Use technical scheme of the present invention, have following technique effect: the effective ingredient of (1) SYR-322 composition tablet of the present invention is SYR-322, mannitol, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, magnesium stearate and 5% hydroxypropyl cellulose aqueous solution, have that synthesis material is easy to get, cost is low, and disintegration rate is fast, dissolution rate is high, good stability, dosage accurately, taking convenience, the characteristics such as be easy to carry; (2) to prepare the method step of SYR-322 composition tablet simple in the present invention, and technical process is easily controlled, and is with short production cycle, and production cost is low, is fit to industrial applications; (3) SYR-322 composition film garment piece provided by the invention has increased the stability of tablet, and tablet increases weight little, little on the disintegration rate impact; (4) preparation method of SYR-322 composition film garment piece provided by the invention is simple to operate, with short production cycle, and production cost is low, is fit to suitability for industrialized production.
The specific embodiment
Describe below in conjunction with specific embodiments technical scheme of the present invention in detail, be used for explaining technical scheme of the present invention in this illustrative examples of the present invention and explanation, but not as a limitation of the invention.
In the present invention program, the source of each raw material and quality standard are as shown in table 1 below:
The source of table 1 raw material and quality standard table
Embodiment 1:
Produce 1000 SYR-322 composition tablets that specification is 25mg, the effective ingredient of described SYR-322 composition tablet is SYR-322, mannitol, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, magnesium stearate and 5% hydroxypropyl cellulose aqueous solution, and the consumption of each raw material is as shown in table 2.
Concrete preparation process is as follows:
The first step: sieve, SYR-322 is crossed 100 mesh sieves, mannitol, microcrystalline Cellulose and cross-linking sodium carboxymethyl cellulose are crossed respectively 80 mesh sieves;
Second step: mix, the SYR-322 that weighs up according to quantity after sieving, mannitol, microcrystalline Cellulose and cross-linking sodium carboxymethyl cellulose mix homogeneously are obtained the first mixture, standby;
The 3rd step: granulate, 5% the hydroxypropyl cellulose aqueous solution that weighs up is added soft material processed in the first mixture, granulate after crossing 24 mesh sieves;
The 4th step: the granule of step (3) is dried to moisture at 60 ℃ is not more than 3.5%, cross 20 mesh sieve granulate, add the magnesium stearate mix homogeneously that weighs up, tabletting namely gets the SYR-322 tablet composition again, shown in tabletting process tablet hardness control and to be not less than 8Kg/mm
2
Table 2 raw material use scale
| The supplementary material title | Consumption (g) |
| SYR-322 (g) | 34 |
| Mannitol (g) | 45 |
| Microcrystalline Cellulose (g) | 68 |
| Cross-linking sodium carboxymethyl cellulose (g) | 1.5 |
| Magnesium stearate (g) | 0.8 |
| Hyprolose (g) | 15 |
The indices of the SYR-322 composition tablet that obtains according to this formula and this method is as shown in table 3:
The indices tables of data of table 3 SYR-322 composition tablet
SYR-322 composition tablet synthesis material is easy to get, cost is low, and disintegration rate is fast, dissolution rate is high, good stability, dosage accurately, taking convenience, be easy to carry; Above-mentioned preparation method step is simple, technical process is easily controlled, with short production cycle, production cost is low, be fit to industrial applications.
Embodiment 2:
Produce 1000 SYR-322 composition tablets that specification is 12.5mg, the effective ingredient of described SYR-322 composition tablet is SYR-322, mannitol, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, magnesium stearate and 5% hydroxypropyl cellulose aqueous solution, and the consumption of each raw material is as shown in table 4.
Concrete preparation process is as follows:
The first step: sieve, the active constituents of medicine SYR-322 is crossed 100 mesh sieves, mannitol, microcrystalline Cellulose and cross-linking sodium carboxymethyl cellulose are crossed respectively 80 mesh sieves;
Second step: mix, the SYR-322 that weighs up according to quantity after sieving, mannitol, microcrystalline Cellulose and cross-linking sodium carboxymethyl cellulose mix homogeneously are obtained the first mixture, standby;
The 3rd step: granulate, 5% the hydroxypropyl cellulose aqueous solution that weighs up is added soft material processed in the first mixture, granulate after crossing 24 mesh sieves;
The 4th step: the granule of step (3) is dried to moisture at 60 ℃ is not more than 3.5%, cross 20 mesh sieve granulate, add again the magnesium stearate mix homogeneously that weighs up, measure intermediate content after tabletting namely get the SYR-322 tablet composition, shown in tabletting process tablet hardness control and be not less than 8Kg/mm
2Table 4 raw material use scale
| The supplementary material title | Consumption (g) |
| SYR-322 (g) | 17 |
| Mannitol (g) | 62 |
| Microcrystalline Cellulose (g) | 68 |
| Cross-linking sodium carboxymethyl cellulose (g) | 1.5 |
| Magnesium stearate (g) | 0.8 |
| Hyprolose (g) | 15 |
The indices of the SYR-322 composition tablet that obtains according to this formula and this method is as shown in table 5:
The indices tables of data of table 5 SYR-322 composition tablet
SYR-322 composition tablet synthesis material is easy to get, cost is low, and disintegration rate is fast, dissolution rate is high, good stability, dosage accurately, taking convenience, be easy to carry; Above-mentioned preparation method step is simple, technical process is easily controlled, with short production cycle, production cost is low, be fit to industrial applications.
Embodiment 3:
Adopt the SYR-322 composition tablet of embodiment 1 to make the SYR-322 composition film garment piece that specification is 25mg, fill a prescription as follows:
Preparation method is as follows:
The first step: weigh up Opadry coating powder and water, be mixed and made into coating solution, standby;
Second step: weigh up the SYR-322 composition tablet and put in coating pan, adjusting the coating pan rotating speed is 5-10 rev/min, controlling inlet temperature is that 55-65 ℃ of blowing hot-air makes plain sheet temperature reach 35-45 ℃, spray into the described coating solution of step (1) until coating weightening finish 2.0%～4.0%, the stop-spraying coating solution, determine whether be rotated further coating pan depending on unilateral adhesion degree, then advance drying, namely get SYR-322 composition film garment piece.
Carry out influence factor's test under high temperature (40 ℃, 60 ℃), high humidity (75%RH, 92.5%RH) and illumination (4500lx) condition, emphasis is investigated appearance character, content and the related substance of tablet and be the results are shown in Table shown in 6:
Table 6 SYR-322 composition film garment piece influence factor test
Annotate: this film is moisture absorption weightening finish moisture absorption weightening finish 8.02% after 2.29%, 10 day after 92.5%RH places 5 days; Moisture absorption weightening finish moisture absorption weightening finish 2.95% after 0.83%, 10 day after 75%RH places 5 days.
Experimental result shows, this preparation was placed 5,10 days under high humidity, illumination (4500lx) condition, and every investigation index was compared with 0 day and had no significant change, and related substance slightly increases under 60 ℃ of conditions, related substance is without significant change, so suggestion this product room temperature is preserved under 40 ℃ of conditions
SYR-322 composition film garment piece provided by the invention has increased the stability of tablet, and tablet increases weight little, little on the disintegration rate impact; The preparation method of SYR-322 composition film garment piece provided by the invention is simple to operate, with short production cycle, and production cost is low, is fit to suitability for industrialized production.
Embodiment 4:
Adopt the SYR-322 composition tablet of embodiment 2 to make the SYR-322 composition film garment piece that specification is 12.5mg, fill a prescription as follows:
Preparation method is as follows:
The first step: weigh up Opadry coating powder and water, be mixed and made into coating solution, standby;
Second step: weigh up the SYR-322 composition tablet and put in coating pan, adjusting the coating pan rotating speed is 5-10 rev/min, controlling inlet temperature is that 55-65 ℃ of blowing hot-air makes plain sheet temperature reach 35-45 ℃, spray into the described coating solution of step (1) until coating weightening finish 2.0%～4.0%, the stop-spraying coating solution, determine whether be rotated further coating pan depending on unilateral adhesion degree, then advance drying, namely get SYR-322 composition film garment piece.
Carry out influence factor's test under high temperature (40 ℃, 60 ℃), high humidity (75%RH, 92.5%RH) and illumination (4500lx) condition, emphasis is investigated appearance character, content and the related substance of tablet, the results are shown in Table shown in 7:
Table 7 SYR-322 composition film garment piece influence factor tests (specification 12.5mg)
Annotate: this film is moisture absorption weightening finish moisture absorption weightening finish 8.31% after 1.58%, 10 day after 92.5%RH places 5 days; Moisture absorption weightening finish moisture absorption weightening finish 2.52% after 1.02%, 10 day after 75%RH places 5 days.
Experimental result shows, this preparation was placed under high humidity, illumination condition 5,10 days, and every investigation index was compared with 0 day and had no significant change, and related substance slightly increases under 60 ℃ of conditions, related substance is without significant change, so suggestion this product room temperature is preserved under 40 ℃ of conditions.
SYR-322 composition film garment piece provided by the invention has increased the stability of tablet, and tablet increases weight little, little on the disintegration rate impact; The preparation method of SYR-322 composition film garment piece provided by the invention is simple to operate, with short production cycle, and production cost is low, is fit to suitability for industrialized production.
Embodiment 5:
Adopt the formula of embodiment 3 to carry out scale-up, the concrete consumption of raw material is as shown in table 8 below:
Table 8 specification is the SYR-322 composition film garment piece scale-up raw material consumption of 25mg
Control parameter in concrete technology as shown in table 9:
The control table of table 9 key process parameter
The result demonstration, in amplification process, the equal practical of the formulation and technology of this specification preparation, process stabilizing.Sample to preparation carries out the index investigation with reference to embodiment 3, and indices all meets the clinical research quality standard.
Embodiment 6:
Adopt the formula of embodiment 4 to carry out scale-up, lot number is WA110517, WA110519, WA110521, and the concrete consumption of raw material is as shown in table 10 below:
Table 10 specification is the SYR-322 composition film garment piece scale-up raw material consumption of 12.5mg
Control parameter in concrete technology as shown in table 11:
The control table of table 11 key process parameter
The result demonstration, in amplification process, the equal practical of the formulation and technology of this specification preparation, process stabilizing.Sample to preparation carries out the index investigation with reference to embodiment 4, and indices all meets the clinical research quality standard.
Detecting instrument and the detection method thereof used in above embodiment 1, embodiment 2, embodiment 3, embodiment 4, embodiment 5 and embodiment 6 techniques are summed up as follows:
1, pellet moisture: adopt the Ka Shi micro-water analyzer, with reference to " two appendix VIII M first method A of Chinese pharmacopoeia version in 2010 measure pellet moisture.
2, the tablet friability checks: adopt the tablet friabilator, with reference to " two appendix XG of Chinese pharmacopoeia version in 2010 check.
3, check tablet hardness and disintegration: adopt tablet four-function analyzer, with reference to " two appendix XA of Chinese pharmacopoeia version in 2010 check.
4, dissolution test: with reference to " Chinese pharmacopoeia version (two ones) dissolution method (appendix X C the second method) in 2010, specific as follows:
Take water 900ml as dissolution medium, rotating speed is per minute 50 to turn, operation in accordance with the law, through 30 minutes, getting solution filters in right amount, get subsequent filtrate (sample concentration 12.5 μ g/ml) as need testing solution, it is appropriate that another precision takes the SYR-322 reference substance, is diluted to Egelieting that every 1ml approximately contains 12.5 μ g product solution in contrast with dissolution medium; Get respectively above-mentioned two kinds of solution and measure trap in 275nm wavelength place, calculate the stripping quantity of every.
5, related substance inspection: with reference to SYR-322 raw material detection method, the photograph high performance liquid chromatography (" two appendix V D of Chinese pharmacopoeia version in 2010) measure.
(1) chromatographic condition: the detection wavelength is 224nm, and column temperature is 30 ℃, and flow velocity is 1.0ml/min, and number of theoretical plate is not less than 3000 by SYR-322.
(2) mobile phase A be 0.1% high chloro acid solution (containing 0.3% triethylamine) (pH=3.0), Mobile phase B is acetonitrile, shown in table 12 specific as follows:
The mapping table of table 12 mobile phase A and Mobile phase B and time
| Time (minute) | Mobile phase A (%) | Mobile phase B (%) |
| 0 | 80 | 20 |
| 10 | 80 | 20 |
| 20 | 55 | 45 |
| 30 | 55 | 45 |
| 31 | 80 | 20 |
| 40 | 80 | 20 |
(3) system suitability: get SYR-322 and impurity F 1008 each approximately 5mg put respectively in 10ml and 1000ml measuring bottle, adding the initial flow mutual-assistance dissolves and is diluted to scale, shake up, get respectively above-mentioned two kinds of solution 2ml mixings, precision measures mixed solution 20 μ l injection liquid chromatographies, record chromatogram (peak sequence is followed successively by Egelieting, benzoic acid and impurity F 1008), number of theoretical plate is not less than 3000 by Egelieting peak calculating.
(4) algoscopy: get this product, porphyrize, precision takes fine powder appropriate (approximately being equivalent to SYR-322 10mg) and puts in the 20ml volumetric flask, add the initial flow phased soln and dilute and put scale, filter, make the solution that every 1ml approximately contains 0.5mg, as need testing solution; Precision measures need testing solution 20 μ l, and injection liquid chromatography respectively records chromatogram to 5 times of main constituent peak retention time.After the deduction solvent peak, if any impurity peaks, detect single maximum contaminant and total impurities content in the need testing solution chromatogram.
6, assay: with reference to SYR-322 raw material detection method, measure according to high performance liquid chromatography (two appendix V D of Chinese Pharmacopoeia version in 2010).
Chromatographic condition is as follows with reference to the chromatographic condition that related substance checks:
Chromatographic column: YMC C18 post;
Mobile phase: (pH=3.0)=20:80 of acetonitrile-0.1% perchloric acid (containing 0.3% triethylamine);
Survey wavelength: 224nm;
Column temperature: 30 ℃;
Sample size: 20 μ l;
Method: get this product, porphyrize, precision takes fine powder appropriate (approximately being equivalent to SYR-322 12.5mg), puts in the 25ml volumetric flask, adds mobile phase and dissolves and dilute and put scale, shakes up filtration; Precision measures 1ml and puts in the 10ml volumetric flask, adds mobile phase and is diluted to scale, shakes up, and gets need testing solution.It is appropriate that another precision takes reference substance, is made in the same way of every 1ml and approximately contains 50 μ g SYR-322 solution, product solution in contrast.Precision measures need testing solution and reference substance solution 20 μ l injection liquid chromatographies, records chromatogram, presses external standard method with calculated by peak area this product content.
7, enantiomer inspection: with reference to SYR-322 raw material detection method, measure according to high performance liquid chromatography (two appendix V D of Chinese Pharmacopoeia version in 2010).
Get this product appropriate, add mobile phase and dissolve and dilute and make the solution that every 1ml approximately contains 25 μ g SYR-322s, shake up, as need testing solution; Separately get the SYR-322 raceme appropriate, add mobile phase and dissolve and dilute and make the solution that every 1ml approximately contains 25 μ g, as system test solution.Be chromatographic column with the CBH chiral column, with water (disodiumedetate of the Ammoniom-Acetate of 10mM and 50 μ M is transferred PH to 6.0 with glacial acetic acid): methanol=95:5 is mobile phase, and flow velocity is 0.2ml/ minute, and the detection wavelength is 224nm.Get system test solution 20 μ l injection liquid chromatographies, record chromatogram, the separating degree between each composition should be less than 1.5.Precision measures need testing solution and each 20 μ l of contrast solution, and the injection liquid chromatography, record chromatogram respectively.
The above is the preferred embodiment of the present invention; should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the principle of the invention; can also make some improvements and modifications, these improvements and modifications also are considered as protection scope of the present invention.
Claims (10)
1. SYR-322 composition tablet, it is characterized in that: in parts by weight, the effective ingredient of described SYR-322 composition tablet is 15 parts of 34 parts of SYR-322s, 45 parts, mannitol, 68 parts of microcrystalline Cellulose, 1.5 parts of cross-linking sodium carboxymethyl celluloses, 0.8 part of magnesium stearate and 5% hydroxypropyl cellulose aqueous solutions.
2. SYR-322 composition tablet, it is characterized in that: in parts by weight, the effective ingredient of described SYR-322 composition tablet is 15 parts of 17 parts of SYR-322s, 62 parts, mannitol, 68 parts of microcrystalline Cellulose, 1.5 parts of cross-linking sodium carboxymethyl celluloses, 0.8 part of magnesium stearate and 5% hydroxypropyl cellulose aqueous solutions.
3. the preparation method of a SYR-322 composition tablet as claimed in claim 1 is characterized in that: in parts by weight, comprise the following steps:
(1) sieve: SYR-322 is crossed the 90-110 mesh sieve, with mannitol, microcrystalline Cellulose and the cross-linking sodium carboxymethyl cellulose 70-95 mesh sieve that sieves respectively;
(2) mix: take the SYR-322 of 34 parts after step (1) is sieved, the mannitol of 45 parts, the microcrystalline Cellulose of 68 parts and the cross-linking sodium carboxymethyl cellulose mix homogeneously of 1.5 parts and obtain the first mixture, standby;
(3) granulate: 5% hydroxypropyl cellulose aqueous solutions of 15 parts are added soft material processed in described the first mixture, excessively granulate after the 20-25 mesh sieve;
(4) granule of step (3) is dried to moisture at 60 ℃ and is not more than 3.5%, cross granulate after the 15-25 mesh sieve, then add the magnesium stearate mix homogeneously of 0.8 part, measure intermediate content after tabletting namely get the SYR-322 tablet composition.
4. the preparation method of a SYR-322 composition tablet as claimed in claim 2 is characterized in that: in parts by weight, comprise the following steps:
(1) sieve: SYR-322 is crossed the 90-110 mesh sieve, with mannitol, microcrystalline Cellulose and the cross-linking sodium carboxymethyl cellulose 70-95 mesh sieve that sieves respectively;
(2) mix: take the SYR-322 of 17 parts after step (1) is sieved, the mannitol of 62 parts, the microcrystalline Cellulose of 68 parts and the cross-linking sodium carboxymethyl cellulose mix homogeneously of 1.5 parts and obtain the first mixture, standby;
(3) granulate: 5% the hydroxypropyl cellulose aqueous solution of 15 parts is added soft material processed in the first mixture, granulate after crossing the 20-25 mesh sieve;
(4) granule of step (3) is dried to moisture at 60 ℃ and is not more than 3.5%, cross granulate after the 15-25 mesh sieve, then add the magnesium stearate mix homogeneously of 0.8 part, measure intermediate content after tabletting namely get the SYR-322 tablet composition.
5. the preparation method of according to claim 3 or 4 described SYR-322 composition tablets, it is characterized in that: the SYR-322 described in step (1) is crossed 100 mesh sieves, and described mannitol, microcrystalline Cellulose and cross-linking sodium carboxymethyl cellulose are crossed respectively 80 mesh sieves.
6. the preparation method of according to claim 3 or 4 described SYR-322 composition tablets, is characterized in that: sieving as crossing 24 mesh sieves in step (3).
7. the preparation method of according to claim 3 or 4 described SYR-322 composition tablets, is characterized in that: sieving as crossing 20 mesh sieves in step (4).
8. the preparation method of according to claim 3 or 4 described SYR-322 composition tablets is characterized in that: in step (4) in the tabletting process tablet hardness control and be not less than 8Kg/mm
2
9. SYR-322 composition film garment piece is characterized in that: in parts by weight, made by claim 1 or 2 described SYR-322 composition tablets and stomach dissolved film coating pre-mix dose;
150 parts of described SYR-322 composition tablets;
Described stomach dissolved film coating pre-mix dose is made by the Opadry coating powder of 16.0-16.5 part and the water of 84 parts.
10. preparation method of SYR-322 composition film garment piece as claimed in claim 9 is characterized in that: comprise the following steps:
(1) weigh up Opadry coating powder and water, be mixed and made into coating solution, standby;
(2) weighing up the SYR-322 composition tablet puts in coating pan, adjusting the coating pan rotating speed is 5-10 rev/min, controlling inlet temperature is that 55-65 ℃ of blowing hot-air makes plain sheet temperature reach 35-45 ℃, spray into the described coating solution of step (1) until coating weightening finish 2.0%～4.0%, the stop-spraying coating solution, determine whether be rotated further coating pan depending on unilateral adhesion degree, then advance drying, namely get SYR-322 composition film garment piece.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101058594A CN103156819A (en) | 2013-03-29 | 2013-03-29 | Benzoic acid alogliptin composition troche and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101058594A CN103156819A (en) | 2013-03-29 | 2013-03-29 | Benzoic acid alogliptin composition troche and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103156819A true CN103156819A (en) | 2013-06-19 |
Family
ID=48580687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013101058594A Pending CN103156819A (en) | 2013-03-29 | 2013-03-29 | Benzoic acid alogliptin composition troche and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103156819A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103353491A (en) * | 2013-06-29 | 2013-10-16 | 北京万全德众医药生物技术有限公司 | Method for separating and determining alogliptin benzoate raw material and preparation thereof by liquid chromatography |
| CN103610661A (en) * | 2013-11-22 | 2014-03-05 | 迪沙药业集团有限公司 | Composition |
| CN104569172A (en) * | 2014-11-05 | 2015-04-29 | 广东东阳光药业有限公司 | A method for detecting the dissolution rate of alogliptin benzoate tablets by liquid chromatography |
| CN104721188A (en) * | 2013-12-20 | 2015-06-24 | 中美华世通生物医药科技（武汉）有限公司 | Stable composition containing Alogliptin benzoate |
| CN105203678A (en) * | 2015-07-10 | 2015-12-30 | 迪沙药业集团有限公司 | Method for measuring optical purity of R-alogliptin benzoate |
| CN105796514A (en) * | 2014-12-31 | 2016-07-27 | 江苏万邦生化医药股份有限公司 | Alogliptin benzoate oral disintegrating tablet and preparation method thereof |
| CN106913555A (en) * | 2017-02-04 | 2017-07-04 | 辰欣药业股份有限公司 | A kind of preparation method of the SYR-322 piece of high bioavilability |
| CN107744499A (en) * | 2017-11-30 | 2018-03-02 | 常州市阳光药业有限公司 | SYR-322 oral administration solution and preparation method thereof |
| CN105527348B (en) * | 2014-09-28 | 2018-07-24 | 中美华世通生物医药科技（武汉）有限公司 | Separation analysis alogliptin benzoate preparation and its method in relation to substance |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101646420A (en) * | 2007-02-01 | 2010-02-10 | 武田药品工业株式会社 | Solid preparation containing alogliptin and pioglitazone |
-
2013
- 2013-03-29 CN CN2013101058594A patent/CN103156819A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101646420A (en) * | 2007-02-01 | 2010-02-10 | 武田药品工业株式会社 | Solid preparation containing alogliptin and pioglitazone |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103353491A (en) * | 2013-06-29 | 2013-10-16 | 北京万全德众医药生物技术有限公司 | Method for separating and determining alogliptin benzoate raw material and preparation thereof by liquid chromatography |
| CN103353491B (en) * | 2013-06-29 | 2018-11-16 | 北京万全德众医药生物技术有限公司 | A method of with liquid chromatography for separating and determining alogliptin benzoate raw material and its preparation |
| CN103610661A (en) * | 2013-11-22 | 2014-03-05 | 迪沙药业集团有限公司 | Composition |
| CN103610661B (en) * | 2013-11-22 | 2017-09-12 | 威海迪素制药有限公司 | A kind of composition |
| CN104721188A (en) * | 2013-12-20 | 2015-06-24 | 中美华世通生物医药科技（武汉）有限公司 | Stable composition containing Alogliptin benzoate |
| CN105527348B (en) * | 2014-09-28 | 2018-07-24 | 中美华世通生物医药科技（武汉）有限公司 | Separation analysis alogliptin benzoate preparation and its method in relation to substance |
| CN104569172A (en) * | 2014-11-05 | 2015-04-29 | 广东东阳光药业有限公司 | A method for detecting the dissolution rate of alogliptin benzoate tablets by liquid chromatography |
| CN105796514A (en) * | 2014-12-31 | 2016-07-27 | 江苏万邦生化医药股份有限公司 | Alogliptin benzoate oral disintegrating tablet and preparation method thereof |
| CN105203678A (en) * | 2015-07-10 | 2015-12-30 | 迪沙药业集团有限公司 | Method for measuring optical purity of R-alogliptin benzoate |
| CN106913555A (en) * | 2017-02-04 | 2017-07-04 | 辰欣药业股份有限公司 | A kind of preparation method of the SYR-322 piece of high bioavilability |
| CN107744499A (en) * | 2017-11-30 | 2018-03-02 | 常州市阳光药业有限公司 | SYR-322 oral administration solution and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103156819A (en) | Benzoic acid alogliptin composition troche and preparation method thereof | |
| CN106924208A (en) | A kind of compound Dapagliflozin Metformin Extended-release Tablets and preparation method thereof | |
| CN103127018A (en) | Levamlodipine besylate tablet and preparation method thereof | |
| CN101695480A (en) | Olopatadine hydrochloride dispersible tablets, preparation method thereof and quality control method thereof | |
| CN101647785B (en) | Gliclazide sustained-release tablet and preparation method thereof | |
| CN104644578A (en) | Sitagliptin phosphate composition tablet and preparation method thereof | |
| CN102688252A (en) | Acarbose oral solid preparation composition and preparation method thereof | |
| CN101322694A (en) | Piclofenac potassium sustained release tablets and preparing technique thereof | |
| CN105456270A (en) | Dipeptidyl peptidase IV inhibitor pharmaceutical composition, use and preparation method thereof | |
| CN117717533B (en) | Epalrestat sustained-release composition, preparation method and application thereof | |
| CN103385876A (en) | Frovatriptan medicine composition and preparation method thereof | |
| CN102232935A (en) | Novel oral mecobalamin sustained-release tablets and preparation method thereof | |
| CN102772395A (en) | Sustained release preparation containing ambroxol hydrochloride and clenbuterol hydrochloride, and preparation method thereof | |
| CN105796519A (en) | Pramipexole dihydrochloride sustained-release tablet and preparation method thereof | |
| CN105853386B (en) | Tablet containing dapagliflozin propylene glycol hydrate and preparation method thereof | |
| CN100496487C (en) | Mitiglinide preparation and preparing method | |
| CN107080737A (en) | A kind of preparation method for the Olanzapine oral disnitegration tablet for treating depression | |
| CN102600149B (en) | Pharmaceutical composition for treating diabetes | |
| CN108670958A (en) | A kind of preparation method of voglibose effervescent tablet | |
| CN101874792B (en) | Phloroglucinol oral disintegrating tablet and preparation method thereof | |
| CN103432090B (en) | A kind of sublingual tablet of Huowei Buxusing D and its preparation method and application | |
| CN101829068A (en) | Water soluble medicament sustained-release tablets and preparation method thereof | |
| CN101537002B (en) | Diacerein composition with excellent dissolution performance and preparation and application thereof | |
| CN104352540B (en) | It is a kind of to treat hydrogel matrix type sustained release tablets of coronary disease and angina pectoris and preparation method thereof | |
| CN104069080A (en) | Prucalopride succinate tablet composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130619 |